• General multiple sclerosis (MS)
  • MS - Dimethyl fumarate
    • The areas of research currently being considered to support studies related to delayed-release dimethyl fumarate (DMF) in multiple sclerosis can be found below.

      In scope:  

      1. Comparative effectiveness as assessed by clinical, MRI, biomarker endpoints as well as PROs vs newer DMTs in the treatment of naïve as well as switch patients
      2. Assessment of management strategies related to DMF adherence
      3. Studies deciphering the MoA of dimethyl fumarate including its neuroprotective potential, how it may cause lymphopenia and/or GI symptoms

      Out of scope:

      1. Fluid biomarker studies trying to identify specific responder populations among patients treated with dimethyl fumarate
      2. Single site studies on clinical efficacy and/or electrophysiological measures or OCT

      Of note: Study designs for research objectives that have been well-researched in the past need to be powered to derive statistically meaningful conclusions and provide new scientific observations.

      Research support is awarded on a highly competitive basis, and submission of research proposals in these areas of interest does not guarantee that support will be awarded.

  • MS - Natalizumab
  • MS - Peginterferon beta-1a
  • MS - Prolonged-release fampridine